Bristol/Otsuka Get Priority Review For Abilify In Patients As Young As 10 With Bipolar Disorder
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee date for pediatric bipolar indication is likely March or April 2008.
You may also be interested in...
Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.
Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.
Bristol/Otsuka’s Abilify Gets FDA Nod For Use In Combination With Antidepressants
Aripiprazole becomes first drug approved as add-on treatment for major depressive disorder.